Nano-Syringe Delivers Combination, Targeted Brain Cancer Therapy
THE METHODIST HOSPITAL SYSTEM
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. Patients with glioblastoma multiforme (GBM), the most common and aggressive malignant primary brain tumor, typically have a prognosis of 14-month median survival time despite medical interventions, which currently include surgery, chemotherapy and radiation. The Rice-Methodist group developed the hydrophilic carbon cluster (HCC) antibody drug enhancement system (HADES), named after the Greek god of the underworld. Through a 20-nanometer syringe, which is 2 million times smaller than a coffee mug, this nanovector successfully delivered a combination of three chemotherapy drugs into GBM cells in vivo, resulting in a high kill rate. Learn more at http://bit.ly/IKfocN.